HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• HYMPAVZI reduced bleeds by 93% compared to on-demand treatment with bypassing agents in adults and adolescents with hemophilia A or B with inhibitors

  80% confidence

• The emergence of inhibitors poses significant treatment challenges and can increase disease burden for people living with hemophilia A or B

  80% confidence

• More than 800,000 people in the world live with hemophilia A or hemophilia B

  80% confidence

• HYMPAVZI demonstrates potential as a safe and efficacious treatment option that significantly reduced bleeding episodes and improved certain aspects of health-related quality of life

  80% confidence

• Pfizer continues its ongoing effort spanning more than 40 years to improve hemophilia care

  80% confidence

• Approximately 20% of people with hemophilia A and 3% of people with hemophilia B develop inhibitors to factor replacement therapies

  80% confidence

• The data demonstrate the potential of HYMPAVZI to combine efficacy, safety, and straightforward administration for adults and adolescents living with hemophilia A or B with inhibitors

  80% confidence

Data points we hold from this source